The Real-World Effectiveness of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Adults in Alberta, Canada: A Retrospective Population-Based Cohort Study.

ABSTRACT: Background: In clinical trials, pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) or tenofovir alafenamide-emtricitabine (TAF/FTC) is up to 99% efficacious in preventing human immunodeficiency virus (HIV) infection. The real-world effectiveness of PrEP has not been extensively evaluated in Canada. Methods: This population-based cohort included adults without HIV as determined by viral serology and ICD-9/ICD-10 codes from Alberta with ≥ 3 months of PrEP prescriptions. It used provincial administrative data. Patients were followed from their first PrEP prescription until diagnosed HIV infection or censoring. Cox proportional hazard models were used to identify independent predictors of HIV infection. Results: A total of 4750 adult

SUBMITTER: Rennert May E 

PROVIDER: S-EPMC12358228 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature